Podcasts about Myosin

What if the darkest chapter of your life turned out to be the very thing that saved it? Sean Clayton is a serial entrepreneur, marketing expert, and founder of Myosin and Mindful Ventures. He has helped bring nine brands to exit totaling over a billion dollars through direct-to-consumer marketing. Today, he is building AI-first marketing products, investing in over 30 companies, and teaching people how to unlock their highest self through integrated spirituality and radical inner work. In this conversation on The Greatness Machine, Darius and Sean dig into one of the most remarkable origin stories you'll hear on this show. Sean opens up about childhood sexual abuse and the deep wounds it left behind, the people-pleasing and affirmation-seeking patterns it created, and the moment he tried to end his life before everything fell apart. He shares how a federal conviction and nearly three years behind bars paradoxically became the turning point that broke a cycle that could have killed him, and how he rebuilt his life from the ground up, starting at a car dealership in a halfway house with $200 in ads and a hunger to prove the world wrong. Sean also shares the spiritual framework he now teaches through the Miracle Academy, including how to get in communion with your inner child, why everything happening outside of you is simply a feedback loop of your internal world, how to recognize and create from life's patterns, and what it truly means to stop efforting through life and start walking in greatness. In this episode, Darius and Sean will discuss: (00:00) Welcome to The Greatness Machine (02:56) Sean Clayton's Journey in Marketing (05:45) Overcoming Adversity: Sean's Personal Story (08:31) The Impact of Criminal Charges on Life (11:35) Navigating the Prison System (14:06) Lessons Learned and Marketing Success (17:12) The Future of Marketing and AI (21:20) From Harvard to Houston: A Journey of Rebellion (28:05) Navigating Corporate Challenges: The Rise and Fall of Innovations (36:02) Transforming Trauma: Finding Purpose Through Pain (41:41) The Gift of Trauma: Testing Worthiness and Growth (44:10) The Influence of the Inner Child (46:49) Aligning with Your Higher Self (50:01) Miracles of Life and Purpose (01:03:14) Embodiment and Self-Truth Sean Clayton is a visionary entrepreneur and marketing expert with a rare ability to blend data-driven strategy with human-centered storytelling. He is the founder of Myosin, a full-service growth marketing accelerator, and has helped bring nine brands to exit totaling over a billion dollars in value through direct-to-consumer marketing. His work spans venture growth, regenerative health, Web3 user acquisition, and holistic well-being, with notable partnerships alongside industry giants like Lionsgate, Sony, and Fox. Previously serving as Chief Solution Officer at WPP, Sean has built sustainable growth infrastructures for some of the world's leading brands. He is also the creator of the Miracle Academy, a platform dedicated to integrated spirituality, emotional freedom, and personal transformation. A recognized speaker and thought leader, Sean's insights have been featured in TechCrunch, VentureBeat, and Martech Series. His life and career are a testament to what becomes possible when business acumen meets deep inner work. Connect with Sean: Website: https://www.themiracleacademy.com/  Website: https://myosin.io/  YouTube: https://www.youtube.com/@Abundance10000  Instagram: https://www.instagram.com/abundance10000/  Connect with Darius: Website: https://therealdarius.com/ Linkedin: https://www.linkedin.com/in/dariusmirshahzadeh/ Instagram: https://www.instagram.com/imthedarius/ YouTube: https://www.youtube.com/@Thegreatnessmachine  Book: The Core Value Equation https://www.amazon.com/Core-Value-Equation-Framework-Limitless/dp/1544506708 Write a review for The Greatness Machine using this link: https://ratethispodcast.com/spreadinggreatness.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Anjali Tiku Owens, MD - Contemporary Data, Differentiation, and Decision-Making in Hypertrophic Cardiomyopathy: A Guide to Cardiac Myosin Inhibition for the Managed Care Professional

Drs. Maron and Rowin review how treatment for symptomatic obstructive hypertrophic cardiomyopathy has evolved from mainly using beta blockers and invasive procedures to now including newer cardiac myosin inhibitor drugs. These newer medications more reliably reduce obstruction and improve patient symptoms and exercise capacity, but require careful safety monitoring with regular heart function checks.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/WMQ865. CME/MOC/AAPA/IPCE credit will be available until April 28, 2027.Cardiac Myosin Inhibition in the Real World: What Have We Learned From Long-Term Experience in Obstructive HCM? In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc.. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

CME credits: 1.00 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/molecular-precision-how-myosin-inhibitors-redefine-control/54839/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/redefining-ohcm-care-efficacy-and-safety-of-myosin-inhibitors/54840/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-evidence-to-action-integrating-emerging-myosin-inhibitors-into-ohcm-treatment-plans/54841/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-beta-blockers-to-myosin-inhibitors-initial-decision-making-in-obstructive-hcm/54843/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoing symptom burden and functional limitations despite guideline-directed first-line therapy with beta-blockers and analyze mechanistic, pharmacokinetic, and pharmacodynamic differences among available agents, including their effects on peak VO₂, left ventricular outflow tract gradients, and patient-reported outcomes. Through expert discussion and case-based application, the activity highlights practical considerations for treatment selection, individualized dosing and titration, safety monitoring, and treatment transitions to support evidence-based strategies that optimize hemodynamics and improve quality of life in patients with oHCM.*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

In this episode, we sit down with Jay and Shane, Co-Leads of the AI-Enabled Marketer & Growth Guild at Myosin, to unpack what AI-enabled marketing actually looks like in practice.We get into how both of them found their way into crypto and marketing, why AI is no longer optional for modern marketers, and how tools like ChatGPT, Claude Code, n8n, OpenClaw, Higgsfield, and Suno are changing the way teams build, iterate, and ship.We also talk through the thinking behind the AI-Enabled Marketer Skoool community they recently launched, what they're teaching inside it, and why the goal is not hype or course-bro fluff, but practical workflows that help marketers actually do better work.Along the way, we dig into AI literacy, automation, vibe coding, creative production, lead magnets, prompting, and the difference between just watching AI content versus actually building with it.If you've been feeling excited, overwhelmed, or slightly behind on AI, this one is for you.Timestamps00:00 Intro and why AI-enabled marketing matters now04:24 Jay's background, how crypto clicked, and why marketing was the natural lane06:27 Shane's path from journalism and humanitarian work into Web308:41 What “AI-enabled marketing” actually means12:15 Their current AI stack: ChatGPT, Claude, Claude Code, OpenClaw, Higgsfield, Suno, n8n, and more15:40 Why the AI-Enabled Marketer community exists and who it's built for32:32 Live demo: AI literacy quiz, lead magnets, and practical marketing builds40:50 How they're teaching image and video generation for marketers52:13 Rapid fire: underrated tactics, overrated tactics, and biggest lessons from the past yearShow NotesLearn more: https://myosin.xyz/ai-enabled-marketerSkool: https://www.skool.com/the-ai-enabled-marketer/about

In this episode of JACC This Week, Dr. Carolyn Lam and Dr. Harlan Krumholz spotlight a mini-focus issue on hypertrophic cardiomyopathy (HCM), a field undergoing rapid transformation. The discussion centers on the MAPLE-HCM trial comparing aficamten and metoprolol in symptomatic obstructive HCM, highlighting multidomain response analysis and what it means to measure meaningful improvement. Beyond gradients and biomarkers, the conversation explores a critical question: when physiologic surrogates improve, how should we interpret patient-centered outcomes? Framed by the Editor's Page, "What Does Improvement Mean?", this episode examines the evolving role of myosin inhibitors, disease modification, and the tension between surrogate markers and real-world clinical benefit. Additional highlights include disaggregation of Asian ethnicities in heart failure quality-of-care research and emerging evidence on AI-driven ECG models to predict incident heart failure—underscoring JACC's commitment to precision, equity, and innovation. This issue reflects a broader shift across cardiology: transforming once-static diseases into treatable chronic conditions guided by rigorous evidence.

In Episode 49 of Chain Reactions, we sit down with Mashal Waqar, Head of Marketing at Octant, and get a surprise drop-in from Griff Green, Founder of Giveth, to dig into how public goods funding actually works on Ethereum and why it matters more now than ever.We cover:– How Octant's model works: lock GLM, earn ETH, and choose to fund public goods or keep the yield– The surprisingly heated debate over what counts as a "public good" (yes, Pizza DAO came up)– Why blockchain unlocks speed, transparency, and community-driven capital allocation that traditional grants can't match– Griff's wild story of The DAO hack, how edge case funds turned into $200M+, and the launch of the new DAO Security Fund– The case for an Ethereum security coalition and why L2s need to fund shared infrastructureMashal shares her journey from running a media company with tens of millions of readers to burning out, discovering crypto through NFTs and Gitcoin, and co-authoring the first State of Web3 Grants report.We also get into real-world impact stories, from funding water filters in Gaza to helping doctors in Syria get paid through crypto, and why sustainable funding through DeFi yield beats depleting treasuries. Plus, a great riff on AI in public goods, the Zakat use case for crypto, and why execution beats everything.Timestamps00:00 – Intro and what's on everyone's timeline right now02:08 – Welcome to Chain Reactions and introducing Mashal from Octant03:54 – Mashal's journey from media founder to crypto marketer06:28 – How NFTs and Crypto Covens pulled her back into Web308:53 – Co-authoring the first State of Web3 Grants report and discovering Octant10:25 – What Octant is and how the GLM staking model works13:15 – What actually counts as a public good (and the Pizza DAO debate)16:49 – The $1M Ethereum creator round and lessons from vetting 1,000+ applications18:30 – DeFi vaults, sustainable funding, and the new StreamVote experiment23:30 – Why blockchain unlocks faster, more transparent funding than traditional grants26:34 – Remittances, financial access, and the personal case for crypto in emerging markets33:24 – Griff joins: founding Giveth, The DAO hack, and rescuing $200M+ in edge case funds39:21 – The multiplier effect and why matching makes it hard not to donate44:18 – Launching the DAO Security Fund inspired by Octant's model48:45 – AI experiments at Octant, building with AI, and the case for AI in public goods56:29 – Vitalik's L2 tax tweet, Ethereum sustainability, and the need for a security coalition1:00:00 – Rapid fire: execution beats everything and don't count your chickensShow Notes & Mentions

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/MYA865. CME/MOC/AAPA/IPCE credit will be available until December 8, 2026.Hypertrophic Cardiomyopathy Care in the CMI Era: Elevating Outcomes With Cardiac Myosin Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

CME credits: 0.50 Valid until: 21-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-ohcm-the-emerging-role-of-cardiac-myosin-inhibitors/33176/ Hypertrophic cardiomyopathy (HCM) management is being transformed by advances in diagnostics and the emergence of targeted therapies. In this program, leading international experts review challenges in early recognition, the evolving role of beta-blockers and traditional therapies, and the clinical impact of novel cardiac myosin inhibitors. Data from pivotal studies—including the landmark MAPLE-HCM trial—are examined in depth, with a focus on exercise capacity, gradient reduction, biomarkers, and patient outcomes. Faculty also share practical strategies for patient selection, monitoring, and translating trial evidence into daily cardiology practice. =

Jay from AxonDAO breaks down decentralized science in plain English: giving people ownership of health data, enabling ethical AI insights, and funding research via a governed community. We cover live use cases like A+Voice (voice biomarkers for early Alzheimer's/dementia signals) and CureRING+CureOS (a data vault + wearable), plus how AxonDAO supports external researchers and projects (e.g., LymeDAO). Jay also shares a sharp playbook for storytelling, positioning, and growth in frontier tech—who to learn from, what to avoid, and how to keep product, narrative, and feedback loops tight.Key Timestamps[00:00:00] Intro — science x AI x Web3 [00:01:05] Jay's path: SA banking → security → tech → crypto[00:02:40] What AxonDAO is (and isn't): DeSci, data ownership, ethical AI, funding [00:03:35] Projects: A+Voice (voice biomarker analysis)[00:04:35] CureRING + CureOS: wearable + personal health data vault [00:05:45] How AxonDAO supports researchers (network, platform, milestone funding) [00:07:05] Why not start with hospitals/gov data? Design partners and product truth [00:08:20] The hard part of marketing DeSci; proving the model [00:09:35] Explaining DeSci to family: “the commons for science” [00:10:45] Selecting projects: societal value, acceleration potential, founder grit [00:12:05] Storytelling that converts: category, positioning, emotional resonance [00:13:20] Shout-outs: Myosin's Simon Yi; Celestia's Ekram Ahmed; BioProtocol [00:14:40] Three growth tips: talk to users; avoid shiny pivots; roadmap with feedback [00:16:50] Host's advice: ask better questions; product > marketing > sales [00:18:10] Vision (2–3 yrs): self-sovereign health data; infra for global researchers [00:20:05] Challenges ahead: crowded wearables; agentic AI UX; controlled growth [00:21:05] The Ask: Series A opening; looking for ML/AI talent; links & contactConnecthttps://www.axondao.io/https://x.com/Axondaohttps://www.linkedin.com/in/jarrod-frankel/https://x.com/jay_franks91DisclaimerNothing mentioned in this podcast is investment advice and please do your own research. Finally, it would mean a lot if you can leave a review of this podcast on Apple Podcasts or Spotify and share this podcast with a friend.Be a guest on the podcast or contact us - https://www.web3pod.xyz/

Try Katy's Virtual Studio Free for 7 Days!This Episode's Show NotesJoin Our Newsletter: Movement Colored GlassesIf you have heard about eccentric exercise but are unsure of the benefits, what it is or how to do it, this episode is your primer! Eccentric muscle contractions generate more force with less energy than other types of muscle contraction and are therefore one of the best ways to get stronger. The mechanism of eccentric contraction within the muscle is a little complicated but Katy offers a simple analogy involving two hair combs! Katy and Jeannette offer some examples of how you can incorporate eccentrics into your movement plan with the empowering message that you can get a lot stronger doing only half an exercise. Can't do a pull-up? Not a problem, train the eccentric half of the movement—lowering down from the pull-up bar—and you will reap the strength rewards. Also in this episode, Katy speaks with Pack Matthews of Ikaria Design and creator of the Soul Seat®, the original and adjustable cross-legged chair. Katy is using one for her podcast set up and she and Pack talk about the origin of the chair, how the design has changed over time and Katy's experience with it.  CHAPTERS(0:07:08) - Muscle Contraction: Three types (0:15:56) - Sarcomere: Actin, Myosin, and Titin (0:26:57) - Get Stronger Doing Half of an Exercise (0:41:00) - Listener Question: 'use it or lose it' brought to you by Earth Runners  (0:47:40) - Interview with Pack Matthews of Ikaria Design BOOKS, ARTICLES AND RESEARCH MENTIONEDWant to Get Stronger and Avoid Injury, Try This, New York Times article on eccentrics Eccentrics: Get Stronger Doing Half Of An Exercise, Katy Bowman The Chair by Galen CranzMADE POSSIBLE BY OUR SPONSORS:Ikaria Design, creators of the Soul Seat®, a height adjustable chair that allows you to sit in diverse shapes including cross-legged, take 10% of new inventory with code DNA10Venn Design, beautiful floor cushions and ball seats that keep you moving at home or at the officeSmart Playrooms, design and products to keep you and your kids engaged and active at home, take 10% off monkey bars, rock wall panels and holds with code DNA10Earth Runners, minimalist sandals that mimic being truly barefoot through their grounding technology, take 10% off with code DNA10Peluva, Five-toe minimalist sports shoes ideal for walking and higher impact activities, take 15% off with code NUTRITIOUSMOVEMENTSweet Skins, organic hemp and cotton clothing that is stylish, flexible and designed to move with you, take 15% off with code DNA15

For EP31 of Chain Reactions, we sat down with Bettina Sosa — one of the newest guild leads at Myosin and our DevRel whisperer — to unpack why every founder building in crypto needs to treat Developer Relations as a core part of their go-to-market motion.We trace Bettina's path from researching self-sovereign identity at Imperial College (shoutout to her Venezuelan roots and her early hopes to fix broken ID systems) to helping major DAOs like Aragon and Bankless with their onboarding UX. Along the way, she shares what it was like moving from research to shipping product, how she started writing dev-focused content to demystify EVM and MEV, and why so much DevRel in Web3 misses the mark.We go deep on what great DevRel actually looks like — beyond just hackathons and bounties — and explore everything from niche TG groups and cold outreach to AI learning tools, dev onboarding trends, and the regions everyone's sleeping on (spoiler: it's not just Asia anymore).If you're serious about growing your protocol, building developer ecosystems, or just want to understand why “just having docs” won't cut it — this one's for you.Please enjoy, and as always, don't forget to subscribe, give us a five-star review, and mint the episode at pods.media/myosinxyz!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

For EP22 of Chain Reactions, we talked to Rom (@romully), Design Lead at Myosin.xyz, community building extraordinaire, and one of our top designers and brand builders within the network.Rom has an incredible background as a designer, and we had a really fun conversation all around the importance of brand building in the marketing stack in web3, how early stage founders can get started without big budgets, design trends we're seeing, and so much more.Please enjoy, and as always, be sure to subscribe, give us a five star review, and mint our episode at https://pods.media/myosinxyz!

Watch our panel of experts and get up to speed on hypertrophic cardiomyopathy (HCM) through a series of quickfire questions and teaching points. Credit available for this activity expires: 01/31/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/new-paradigms-hypertrophic-cardiomyopathy-care-gameshow-2025a10002f4?ecd=bdc_podcast_libsyn_mscpedu

For EP18 of Chain Reactions, we talked to Alex Poon, Co-Founder of Scout Game and Charmverse, a friend of Myosin, and now repeat guest on the Myosin.xyz podcast.Scout Game is a fantasy sports game targeting developers, but open for anyone to play. With massive initial traction, we talked to Alex all about Scout Games' origins, how the game itself works, and Scout Games broader ambitions for expanding to more blockchains and ecosystems, and eventually the global open-source dev community at large. We're massively bullish on Scout Game, and think is an excellent listen for anyone who cares about developer marketing, gamification, and how to build products that are both fun and really solve a clear need. Please enjoy, and as always, be sure to subscribe, give us a five star review, and mint our episode at https://pods.media/myosinxyz!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MEX865. CME/MOC/AAPA credit will be available until January 22, 2026.Remodeling Innovation: Applying Clinical Research and Real-World Experience With Cardiac Myosin Inhibition in HCM & Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

For EP16 of Chain Reactions, hot off the release of our Crypto in Argentina report, we talked to Mike Tango Bravo, Founder of Open Vino DAO and a Crecimiento community member, and Tay Todd, our Innovation Genius who helped write Myosin's Crypto in Argentina report. During our chat we talked all about the unique nature of Argentina's economic history and relationship with crypto, and just how and why it's so keen to adopt crypto with even government support and encouragement, as well as the unique and incredible nature of how Open Vino DAO is helping tokenize and democratize access to one of the oldest industries in the world: winemaking.This is a great listen for anyone trying to understand why crypto matters, and how it's fast gaining adoption in countries such as Argentina. Links below! https://bit.ly/myosin-argentina-rr https://x.com/crecimientoar https://openvino.org/

Drs. Gordon Smith, Shahar Shelly, and Teerin Liewluck discuss the correlation between CMAP duration and myosin loss and their effect on mortality by comparing between patients with CIM with and without myosin loss.  Show references: https://www.neurology.org/doi/10.1212/WNL.0000000000209496 

Dr. Gordon Smith talks with Drs. Shahar Shelly and Teerin Liewluck about the correlation between CMAP duration and myosin loss and their effect on mortality by comparing between patients with CIM with and without myosin loss. Read the related article in Neurology.  Disclosures can be found at Neurology.org.